Dermatology company Galderma (SIX: GALD) disclosed on Wednesday that it has received regulatory approval in the EU, US and Canada for a next-generation syringe for its NASHA lidocaine range of Restylane injectable aesthetic products, reinforcing its position in the global aesthetics market.

The newly approved syringe is designed to enhance precision and control through an ergonomic format, improved syringe-needle connection using the Terumo K-Pack Enhance needle, and colour-coded packaging to support ease of use. It is approved for multiple facial indications, including cheeks, chin, jawline and under-eye areas, as well as for use in the hands.

Developed in collaboration with more than 70 practitioners, the device focuses on improved usability, including ease of operation and aspiration, alongside a redesigned premium look and feel. The product also incorporates sustainability features, including fully recyclable paper-based packaging that reduces clinical waste by up to 30%.

The syringe will be used with key products in the Restylane portfolio, including Restylane Lyft Lidocaine, Restylane Eyelight and Restylane-L. The portfolio spans multiple hyaluronic acid technologies designed to deliver tailored aesthetic outcomes across a range of patient needs.

Galderma said the approvals highlight its continued focus on innovation in injectable aesthetics, building on more than 30 years of development and over 77 million treatments administered worldwide.